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SUMMARY:
Rectal cancer is the third most common cancer in men and the second 
most common cancer in women. Among the different treatment options the 
radical approach is performed with a surgical technique known as Total 
Mesorectal Surgery (TME). The use of prophylactic pelvic drainage after 
TME has been long debated. Despite most of the literature agrees about its 
ineffectiveness, there is still controversy over the need of  using it or not: On 
the one hand there are articles supporting the use of drainage and on the 
other hand, articles questioning its use as well as studies that find no 
difference between using them or not.
 Most of the published studies, are inconclusive owing to the 
heterogeneity of the included population, the small number of patients, the 
deficient randomization among other causes; leading to inconsistent results 
and conclusions. For that reason, I have proposed a multicentre study to 
asses the effect of pelvic drainage after Total Mesorectal Excision. 
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        RESUMEN
El cáncer rectal es el tercer cáncer más frecuente en hombres y el 
segundo más común en mujeres. Entre las diferentes opciones terapéuticas, 
encontramos una técnica quirúrgica conocida como Escisión Total de 
Mesorecto (ETM).  El uso de drenaje pélvico tras una ETM ha sido un tema 
muy debatido. A pesar del acuerdo generalizado de la literatura sobre su 
inefectividad,  aún existe controversia sobre la necesidad  o no de usarlo: Por 
un lado, tenemos artículos que apoyan el uso de drenaje y, por el otro lado, 
artículos que lo cuestionan; además de estudios que no encontraron ninguna 
diferencia entre ponerlo y no ponerlo.
La mayoría de los estudios publicados son inconclusos dada la falta de 
heterogeneidad de los mismos, o a su pequeño número de pacientes, o al 
déficit de randomización, entre otras causas; ocasionado así resultados y 
conclusiones inconsistentes. Por esta razón, he propuesto un estudio 
multicéntrico para verificar el efecto del drenaje pélvico tras una Escisión 
Total de Mesorecto. 
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RESUM
El càncer rectal és el tercer càncer que afecta més freqüentment als 
homes i el segon més freqüent a les dones. Entre les diferents opcions 
terapèutiques, trobem una tècnica quirúrgica coneguda com Escissió Toral de 
Mesorrecte. L´us de drenatge pelvic després d´una ETM ha estat un tema 
molt debatut. Tot i que hi ha un acord generalitzat a la literatura sobre la seva 
inefectivitat, encara existeix controvèrsia sobre la necessitat de fer-lo servir o 
no: per un costat, tenim articles que recolzen l´us de drenatge i, per un altre 
costat, articles que ho qüestionen, a més d´estudis que no han trobat cap 
diferencia entre fer-lo i no fer-lo servir.
La majoria dels estudis publicats són inconclusos donada la falta                   
d´heterogeneïtat a l´hora d´incloure la població, o al petit numero de pacients 
o al dèficit de randomitzacio entre altre causes, ocasionant resultats i 
conclusions inconsistents. Per aquesta raó, he proposat un estudi multicentric 
per verificar l´efecte del drenatge pelvià després d´una Escissió Total de 
Mesorecte. 
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COLORECTAL CANCER
Colorectal cancer is the development of cancer from the colon or rectum. 
Worldwide, colorectal cancer is the third most common cancer in men 
(746,000 cases) diagnosed in 2012 and the second most common cancer in 
women (614,000 cases). Annually colorectal cancer is the cause of 
approximately 694,000 deaths (9 per cent of all cancer deaths) across the 
globe. (1) The average age for colon cancer diagnosis is 70 (2)
There is wide geographical variation in incidence across the world 
incidence rates vary ten-fold worldwide, the highest estimated rates being in 
Australia, New Zealand, Europe and North America, and the lowest in 
Western Africa, South and Central Asia. (1) This incidence difference is 
believed to exist as a result of the way in which risk factors are distributed 
worldwide. 
There are many factors that can decrease or increase the risk of suffering 
colorectal cancer:  On the one hand, factors that decrease the risk of colorectal 
cancer are:
 
✓ Physical activity (1,3): a meta-analysis compared the highest and 
lowest total physical activity levels which showed a 20 per cent significant 
decrease in the risk.
✓ Food containing fibre (4)
✓ Wholegrains (5): this meta-analysis showed a significant 17  per cent 
decrease in the risk per 90 grams of wholegrains per day (RR 0.83; 95% CI 
0.78–0.89)
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✓ Dairy products (6): the meta-analysis showed a 13 per cent decrease  
in the risk per 400 grams per day of diary products
✓  Calcium supplements (7): meta-analysis which showed a six per cent 
decrease in the risk per 200 milligrams per day (RR 0.94 (95% CI 0.93–0.96)
✓ Fish (8): meta-analysis which showed an 11 per cent decrease in the 
risk per 100 grams per day (RR 0.89; 95% CI 0.80–0.99);
✓ Vitamin C (9): meta-analysis which showed a six per cent decrease in 
the risk per 40 milligrams of Vitamin C per day (RR 0.94 ; 95% CI 0.89–
0.99)
✓ Vitamin D (10): A study concluded that there is a significant five per 
cent decrease in the risk per 100 IU per day of vitamin D (RR 0.95 (95% CI 
0.93–0.98)
✓ Multivitamin supplements:an analysis comparing users of 
multivitamin supplements with non-user which showed a significant 
decrease in the risk (RR 0.88 ; 95% CI 0.79–0.98))                                                                                     
On the other hand, there are many factors that increase the risk of 
colorectal cancer: 
• Consuming processed meat (11): Processed meats, such as sausages, 
are often cooked at high temperatures, which can lead to increased 
exposure to HCAs and PAHs, which may stimulate tumorigenesis. 
Processed meat is also a source of exogenously derived N-nitroso 
compounds which may have carcinogenic potential 
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• Smoking (9): smoking 40 cigarettes per day increases the risk of 
colorectal cancer by about 40 per cent and nearly doubles the risk of 
colorectal cancer death.
• Alcoholic drinks (12):  study shows that significant increased risks 
were observed for 30 grams per day and above, where the relationship was 
positive and appeared linear 
• Body fatness (13,14,15): Body fatness stimulates the body´s 
inflammatory response, promoting, that way, colorectal cancer. Also, as fat 
promotes cell growth and inhibits apoptosis, it has been linked to greater 
risk of colorectal cancer.
• Red meat (16): red meat increases risk of colorectal cancer as it is rich 
in fat and haem iron
• Low intakes of vegetables and of fruits (17):  the meta-analysis 
showed a significant inverse association per 100 grams of vegetables and 
fruits per day (RR 0.98 (95% CI 0.97–0.99)
•  Food containing haem iron (18): haem iron, which is found at high 
levels in red meat, has been shown to promote colorectal tumorigenesis by 
stimulating the endogenous formation of carcinogenic N-nitroso 
compounds
• Age (19): as we age, the risk of developing colorectal cancer increases. 
Most that 90% of people diagnosed with this type of cancer are older than 
50
• Hereditary conditions: 30% of colorectal cancers run in families. 
About 10% of all colorectal cancers can be traced directly to specific genes. 
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• Polyps in bowel: since colorectal cancers develop from polyps, the 
more polyps a patient has, the greater risk will have to develop this cancer.  
There are many type of polyps. The one that has the highest chance of 
transforming into malignant is the adenomatous polyp. Nowadays, in 
order to prevent any kind of possible malignant transformation, patients 
who have polyps undergo endoscopic polypectomy, or even surgery in 
selected circumstances.(2) 
The mentioned geographical variation in incidence, nowadays has no 
relation with the number of deaths due to colorectal cancer as a result of the 
introduction of screening tests (21). In several parts of Spain there are 
screening programs in which, from age 50 onwards and every two years 
everybody undergoes a physical exam that includes a take-home testing of 
the stool for fecal occult blood (FOBT). If positive result, it will be highly 
recommended to complement  endoscopic tests in order for us to find  and 
remove any polyps (2) or to diagnose a colorectal cancer in its early stages. 
Regular screenings starting at age 50 for people at average risk, have a very 
good chance of catching polyps on their way to becoming cancer, since 
colorectal cancer is typically slow growing, taking five to ten years to 
develop. That way, this screening is not just about detecting cancer early; it 
prevents cancer from arising. 
In reference to the signs and symptoms of colorectal cancer, there are 
usually no symptoms in the early stages. The most common symptom is 
rectal bleeding (22). When a patient has rectal bleeding a differential 
diagnosis must be done between hemorrhoids and anal fissures. Rectal 
bleeding has a positive predictive value (PPV) of just 2,4% (23). Other 
possible symptoms of colorectal cancer include: constipation, diarrhea, 
  7
bloating, loss of weight and appetite, anaemia, vomiting, inability to pass 
stools due to an intestinal blockage (24,25).
To establish a definitive diagnosis, biopsy samples from the colonoscopy 
are needed. Moreover, since 1 out of 25 colorectal cancers present a 
synchronic tumour. In order for us to detect these synchronic lesions a 
complete  colonoscopy must be performed, reaching the ileocecal valve. This  
allows direct identification of another synchronic tumour, histologic 
examination through biopsy, diagnosis and removal of synchronic polyps,… 
(26). The TNM classification system is used as a tool to stage colorectal cancer 
(2). Colorectal cancer staging is performed by using Computed Tomography 
Scan (this test can tell if colon cancer has spread into other organs), 
Ultrasounds, including abdominal ultrasounds (to look for a possible tumour 
spreading in liver, gallbladder, pancreas,or elsewhere in the patient´s 
abdomen), endorectal ultrasound (used to see how far through the real wall 
the cancer has grown and if it reached nearby organs or tissues such as 
lymph nodes), Magnetic Resonance Imaging Scan, Chest X ray (it may be 
done to check if colorectal cancer has spread to the lungs), Positron Emission 
Tomography Scan, Angiography to see the arteries that supply blood to the 
spread tumours and to plan treatments for cancer spread to the liver like 
embolisation.
Regarding the treatment of colorectal cancer, a multidisciplinary team is 
needed. This team includes colorectal surgeons, general surgeons, 
hepatobiliary surgeons, gastroenterologists, medical oncologists, radiation 
oncologists, radiologists, pathologists, geneticists, social workers, oncology 
and surgical nurses and nurse practitioners, enterostomal therapists, and a 
team coordinator.  An interactive discussion is undertaken and a consensus 
built as to the most appropriate plan of treatment and care. (27)
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Treating a colorectal cancer has the main objective of curing the patient 
as well as preserving , when feasible, the sphincter, bladder and sexual 
function. If not possible, then we must try and calm the symptoms moving 
towards a palliative management. (28)
We can find 5 different treatment options:
1.Surgery
2.Radiotherapy 
3.Chemotherapy
4.Antiangiogenic Therapy
5.Anti-EGFR Therapy
Stage 0 Very early cancer on the innermost layer of the intestine
Stage 1 Cancer is in the inner layers of the colon
Stage 2 Cancer has spread through the muscle wall of the colon
Stage 3 Cancer has spread to the lymph nodes
Stage 4 Cancer has spread to other organs
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Firstly, regarding Surgery, it is the standard treatment when the tumor is 
considered local (from Stage I to III). When undergoing surgery, modern 
proctectomy for colorectal cancer is based on a sharp, meticulous extirpation 
of the all the mass with its surrounding pericolorectal lymphatic tissue 
contained within a thin fascial layer, referred to as total mesorectal excision 
(TME):
  10
The following figures show the way how the 
Total Mesorectal Excision technique has to be 
done:
 At the end of the surgery, the healthy sections are reconnected (if this is 
not possible, the surgeon will perform a colostomy). Proper nutrition before 
and after surgery is important for healing and speeding recovery. (29)
Secondly, in respect to Radiotherapy, It may be used alone or in 
combination with other therapies to shrink tumours before surgery or to 
destroy any remaining cancer cells after chemotherapy.(30) Radiation can 
also be used to reduce the tumour size to make a patient more comfortable, 
even when the cancer cannot be removed in locally advanced colorectal 
cancer. 
 Thirdly, apropos the Chemotherapy (highlighting FOLFOX, CapeOX 
and FOLFIRI), it is used in advanced cases (stage II, III and IV). There are 
many different types of chemotherapy drugs, and often, they are used in 
combination to, that way, achieve a more aggressive effect. This is known as 
¨combination therapy,¨ which can also reduce the likelihood that the cancer 
would become resistant to any single chemotherapeutic drug. (31). 
Since 2004, new treatments have been developed called “Targeted 
Therapies,” which are designed to attack specific cell pathways used by 
cancers to survive and grow such as angiogenesis and apoptosis-resistance. 
These new treatments are improving our ability to treat metastatic colorectal 
cancer. (32). We can find the following Targeted Therapies: 
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• Antiangiogenic treatments:
- Bevacizumab (Avastin): it is an antibody drug that binds and 
neutralizes a protein 
called VEGF-A.  
Based on the results 
of the randomized, 
placebo-controlled, 
double blind clinical 
trial called AVF 2107, 
Bevacizumab + 
FOLFOX improved 
median overall 
survival compared to 
those treated with 
chemotherapy alone. 
- Ziv-aflibercept (Zaltrap): it targets proteins VEGF-A, VEGF-B 
(angiogenic factors) and the placental growth factor (PlGF). A 
randomized, double-blind, 
placebo-controlled clinical 
trial called VELOUR which 
studied 1226 patients with 
metastatic colorectal cancer 
whose disease progressed 
during or within 6 months of 
receiving FOLFOX or 
FOLFOX + Bevacizumab, 
found a significant 
improvement in median 
overall survival if patients were treated with Ziv-aflibercept combined 
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with the FOLFIRI chemotherapy, compared to those who received 
chemotherapy alone.
- Regorafenib: it is a 
tyrosine kinase inhibitor 
that targets multiple 
growth factors involved in 
tumor angiogenesis, 
including VEGF receptors, 
Fibroblast Growth Factor 
(FGF) receptors, Platelet-
Derived Growth Factor 
(PDGF) receptors, and the 
angiopoietin receptor 
TIE-2. Regorafenib was approved in 2012 based on the results of the 
randomized, double-blind, placebo-controlled CORRECT trial, which 
enrolled 760 patients with metastatic colorectal cancer previously 
treated with multiple lines of therapies. The results showed a 
significant improvement in median overall survival among patients 
treated with Regorafenib versus those who received placebo. 
• Anti-EGFR treatment: KRAS gene helps doctors customise therapy for 
patients with metastatic colorectal cancer. KRAS tests determine the target 
therapies for which you may be eligible. The drugs Cetuximab and 
Panitumumab are ineffective in tumours that carry mutations of the KRAS 
gene. Roughly 40% of colorectal cancers have KRAS mutations while the 
non-mutated KRAS gene (also known as “wild type”) is found in the 
remaining 60%. Identifying KRAS mutation status avoids unnecessary 
expenses and toxicities from anti-EGFR inhibitors, which are ineffective in 
KRAS mutated colorectal cancers.
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- Cetuximab: It is mainly 
used as a single agent in 
patients who have failed 
previous chemotherapies. (it 
may also be used with 
chemotherapy for first line 
treatment of patients who 
have KRAS mutation-negative 
(wild-type), EGFR-expressing 
mCRC. (33)
- Panitumumab: is used as 
a single agent for treating 
patients with EGFR-
expressing mCRC who have 
experienced progression of 
their disease while or after 
taking a chemotherapy 
regimen.(34)
In  summary,  surgery  is  the  standard  treatment  of  rectal  cancer.  In 
advanced cancer  of  the middle and lower third of  the rectum a radical 
surgery  named  Total  Mesorectal  Excision  (TME)  should  be  performed. 
Although it is a standardized procedure that can be performed in an open, 
laparoscopic or robotic approach, there are still some controversies in its 
management. One of these controversies is if a drainage must be placed or 
not after TME.
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TO DRAIN OR NOT TO DRAIN AFTER TME
The introduction of the Total Mesorectal Excision (TME) by Heald in 
1982 was a major advance in the surgical strategy for rectal cancer, resulting 
in a reduction of local recurrence without adjuvant therapy. In radically 
operated patients, the local recurrence rates with TME after 5 and 10 years 
have been reported to be <10% with a 5-year of survival rate of 80% 
(35,36,37,38). As a result of this procedure, patient satisfaction and quality of 
life has increased since it allows  sphincter preservation in a high percentage 
of patients (39)
Despite all this progress, significant morbidity and mortality may occur. 
The primary concern after a TME surgery is the anastomotic deshicence and 
leakage: its incidence varies from 2 to 25% depending on the level of 
anastomosis (40), tumour diameter, tumour location, and absence of 
protective stoma(41) or method of reconstruction (42,43,44). Also it increases 
the incidence of other deeper complications such as abscesses, peritonitis and 
hematoma. Therefore, among the colorectal surgeons there is a major goal to 
detect any early leak and as a result, prevent the complications that it brings. 
For all these reasons, drainage has been proposed to drain the pelvis after 
colorectal anastomosis (45, 46, 47, 48).
On the one hand, the surgeons who routinely use pelvic drains believe 
that will help detect an early anastomosis leakage (49,50,70). At the same 
time, they defend that the drain avoids the retentions and contamination of 
postoperative pelvic fluid and the consequent sepsis (51,52,53)
 
On the other hand, according to the surgeons who are against the 
routine use of drains, believe that drainage increase the rate of some 
complications (54,55,56), including anastomotic leakage, peritonitis, 
hemorrhage and hematoma. Moreover they argue that also can provoke 
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complications related to the operative wound: abscess, disruption or 
incisional hernia, as well as pulmonary complications (57,58) and intestinal 
obstruction (59).  In addition, drains are thought to promote infection from 
the outside (60), as well as intestinal adhesions (59). Furthermore, they are 
associated with pain, decreasing thoracic compliance leading to 
microatelectasia (57,58). Likewise, they can cause ulcerations of the 
gastrointestinal tract through the drain (61,62),hemorrhage (63), infection of 
the drainage tract (64), intrabdominal retention of the drain (57, 65) 
hampering its removal and wound disruption through the drainage tract 
(65).
As result of its unclear function, many studies have been made in order 
to objectify if placing a drainage makes a positive impact or not after TME 
surgery. 
Firstly, we  will focus in the studies that support the use of prophylactic 
drainage after TME.
Study Type of study Number of 
patients (n)
Main conclusions
Peeters et al. (66) Retrospective 924 patients •Lower rate of anastomotic leakage in 
patients that were drained than in the 
patients were not (9.6% versus 23.5%) 
after TME for rectal cancer located 15 cm 
or less from the anal verge.
•Drains decrease the rate of reoperation.
Que et al. (67) Meta-analysis of 14 
studies (7 
prospective and 7 
retrospective) 
4580 patients Anastomotic leakage was 5,3% in the 
darán grup, versus 23,5% in the non 
drained group.
Rondelli et al (68) Meta-analysis of 8 
studies (3 
randomised clinical 
trials and 5 non-
randomised clinical 
trials)
2277 patients •Lower incidence of extraperitoneal 
colorectal anastomotic leakage in drained 
patients (OR = 0.51; 95% CI: 0.36–0.73).
•Lower reintervention rate in drained 
patients (OR = 0.29; 95% CI: 0.18–0.46). 
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On the other hand, many studies have shown that drains can be an 
independent risk factor for anastomotic leakage and other serious 
complications, inducing more harm than benefit.
There are studies that showed that placing a drainage after a TME 
surgery makes absolutely no difference: it is neither harmful or protective. 
Tsujinaka et al. (69) Retrospective 196 patients Pelvic drainage acts as an early detector 
of anastomotic leakage and reduces the 
need for reoperation 
Type of study Number of 
patients (n)
Main conclusionsStudy
Study Type of study Number of 
pariente (n)
Main conclusions
Urbach et al. (71) Meta-analysis of 4 
randomised 
controlled trials. 
414 patients •Drain group has higher rates of 
wound infection and mortality than 
the non drained group.
•20 of 223 drained patients (8,9%) 
developed anastomotic leakage 
versus 12 of 188 non- drained 
patients (6,4%) 
Petrowsky et al. (72) Meta-analysis of 8 
randomised 
controlled trials 
1390 patients The overall rate of anastomotic 
leakage in drained patients was 
4,2% (30 of 717 patients) versus 2,4% 
(16 of 673 patients) in non-drained 
patients
Karliczek et al. (73) Meta-analysis of 6 
randomised 
controlled trials 
1140 patients Drain group has higher rates 
anastomotic leakage, reintervation 
rates
Zhang et al. (74) Meta-analysis of 11 
randomised 
controlled trials 
1803 patients •Anastomotic leakage rate is higher 
in drained patients ( 67 of 939 ;7,1%) 
than in non-drained patients (50 of 
864; 5,7%)
Menahem et al. (75) Meta-analysis of 3 
randomised 
controlled trials 
660 patients The drained group has higher 
incidence of small  bowel 
obstruction (18,7% versus 12,6%)
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In summary, there is not enough evidence to support or discard the 
routine use of drainage after TME surgery, so we propose a multi centric 
study to try to bring high quality evidence on this subject.
Study Type of study Number of 
pariente (n)
Main conclusions
Rolph et al. (76) Randomised 
controlled trial
908 patients No difference in anastomotic 
leakage rates, mortality, 
reintervention and wound infection. 
Denost et al. (77) Randomised 
controlled trial
469 patients No difference in anastomotic 
leakage rates, mortality, 
reintervention and wound infection, 
Sakr et al. (78) Multivariate analysis 224 patients No difference in anastomotic 
leakage rates, mortality, 
reintervention and wound infection.
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PELVIC DRAINAGE AFTER TOTAL MESORECTAL EXCISION:  
MULTICENTRE STUDY PROPOSAL
Objective:
To asses the effect of pelvic drainage after Total Mesorectal Excision. 
Background:
Although many studies have confirmed infectiveness of drainage, there is 
still a controversy after TME. Moreover, many of the published studies  are 
not conclusive as a result of the heterogeneity of the chosen sample, as well 
as due to the limited sample size and the exclusion of the neo-adjuvant 
therapies which are used in these days in more than 50% of these patients. 
Hypothesis:  
Pelvic drainage after Total Mesorectal Excision does not confer any benefits 
to the patient within the first 30 postoperative days.
Study design: 
A multicenter, open label, randomised study among patients treated for 
rectal cancer is suggested. The patients that fit out inclusion and exclusion 
criteria will be randomized in 2 arms with a ratio 1:1: On the one hand, arm 
¨A¨ will have patients with pelvic suction drain; and on the other hand, arm 
¨B¨ patients without  pelvic drain. The patients´ randomization to one of 
these two groups will be achieved by using a sealed envelope, which for each 
case was opened in the operating room just before finishing the procedure. 
After surgery, patients must be followed during a 6 month period in order to 
check, verify and objectify our endpoints. 
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Endpoints: 
Primary endpoints: 
-Evaluate the rate of pelvic sepsis within 30 days after surgery( process which 
results of an anastomotic leakage)
Secondary endpoints:
-Asses the rate the postoperative mortality within 30 days after surgery.
-Check the number of bowel obstruction cases within 30 days after surgery
-Objectify the reoperation cases due to pelvic sepsis
-Classify the time between rectal excision and the reoperation between the 
drain and no drain patients.
-Evaluate  the length of hospital stay between both groups. 
Methods:
Inclusion criteria:
✓ Total Mesorectal Excision (TME)
✓ Rectal adenocarcinoma, histopathologically proved 
✓ Stage II and III
✓ With or without chemotherapy or radiotherapy neoadjuvant treatment 
✓ Stapled or hand-sewn anastomosis
✓ Open, laparoscopic or robotic approach 
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✓ 18 or more years old
✓ Information of the patient and signature of informed consent 
Exclusion criteria:
• Partial mesorectal excision
• Colonic cancer (>15 cm from the anal verge)
• Abdominoperineal resection
• Simultaneous liver resection
• Multivisceral resection (prostate, seminal bladder, vagina…)
• Total proctocolectomy
• Emergency procedure
• Infected rectal tumor
• Pregnant women
• Women currently nursing 
Preoperative staging:
Preoperative evaluation includes physical examination, colonoscopy with 
biopsy,  pelvic magnetic resonance imaging and abdominal computed 
tomography scan. 
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Surgery: 
 
All patients must have had a preoperative bowel preparation. The operative 
technique could be achieved by open, laparoscopic or robotic approach and 
must include excision of the mesorectum. At the end of the procedure a 
suction pelvic drain will be placed posterior to  the anastomosis (in the pre-
sacral area) for patients randomized in arm A.
Patients in all groups will be treated according the postoperative protocol, 
which includes: evaluation of C-reactive protein at day 3, a computed  
tomography scan when abscess or anastomotic leakage was clinically (fever, 
discharge of pus by the anus or discharge of pus, gas or stools by the vagina 
or drain)  or biologically suspected (C-reactive protein >140mg/L).
The pelvic drain will be removed when the output of the drain will be clear 
and lower than 100 mL/24hours.
Sample Size: 
Our study´s main objective is to compare the postoperative pelvic sepsis 
between the 2 arms within 30 days after surgery. According to literature, 12% 
of patients who undergo TME suffer from pelvic sepsis. Moreover the levels 
of significance must maintain an overall P value of 0,05 according to the O
´Brien-Fleming stopping boundaries. With a 2-sided 5% significance level 
and a power of 80%, an expected rate of 3% of patients for whom a pelvic 
drain would be used even if they were randomized in arm B (due to 
complications during the surgical procedure) and an expected rate of 2% of 
postoperative mortality, an initial sample size of 466 patients is needed 
(software Nquery Advisor v 6.0).
Statistical analysis
Qualitative variables will be described as numbers (percentages) and 
quantitative variables as mean ︎standard deviation. Differences between 
groups will be assessed by x2 tests or Fisher exact tests when appropriate and 
by Student t test P value less than 0.05 is considered as statistically 
significant. Analyses will be by intention to treat. 
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